false
--12-31
0001834105
0001834105
2026-11-17
2026-11-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 17, 2026
IMPACT
BIOMEDICAL INC.
(Exact
name of registrant as specified in its charter)
| Nevada |
|
001-42212 |
|
85-3926944 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
| 275
Wiregrass Pkwy, West Henrietta, New York |
|
14586 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (585) 232-1500
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Ticker
symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.001 par value per share |
|
IBO |
|
The
NYSE American LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Introductory
Note.
This
Current Report on Form 8-K is being filed in connection with the completion of the transactions contemplated by the previously announced
Merger and Share Exchange Agreement, dated as of June 21, 2025, by and among Impact BioMedical Inc., a Nevada corporation (the “Company”
or “Impact”), Zoar Limited (formerly known as Dr Ashleys Limited), a Cayman Islands exempted company limited by shares
(“PubCo”), Dr Ashleys Nevada Sub, Inc., a Nevada corporation and a wholly-owned subsidiary of PubCo (“Merger
Sub”), Zoar Labs Limited (formerly known as Dr Ashleys Bio Labs Limited), a Cayman Islands exempted company limited by shares
(“Zoar”), and Kanans Visvanats (a.k.a. Kannan Vishwanatth), solely in his capacity as the sole shareholder of Zoar
(the “Zoar Shareholder”) (the “Original Agreement”), as amended by the Amended and Restated Amendment
to the Merger and Share Exchange Agreement, dated as of June 30, 2026 (which rescinded and superseded an amendment dated February 27,
2026), and the Second Amended and Restated Amendment to the Merger and Share Exchange Agreement, dated as of August 13, 2026 (the Original
Agreement, as so amended, the “Merger Agreement”).
Item
2.01. Completion of Acquisition or Disposition of Assets.
Pursuant
to the Merger Agreement, on November 17, 2026 (the “Closing Date”), (i) Merger Sub merged with and into the Company
(the “Merger”), with the Company continuing as the surviving corporation and as a wholly-owned subsidiary of PubCo
(the “Surviving Corporation”), and (ii) simultaneously with or immediately following the Merger, PubCo acquired from
the Zoar Shareholder all of the issued and outstanding ordinary shares of Zoar, as a result of which Zoar became a wholly-owned subsidiary
of PubCo (the “Share Exchange” and, together with the Merger and the other transactions contemplated by the Merger
Agreement, the “Business Combination”). The Merger became effective upon the filing of the Articles of Merger with
the Secretary of State of the State of Nevada on the Closing Date (the “Effective Time”).
As
previously reported, the Business Combination and the Merger Agreement were adopted and approved by the Company’s stockholders
at the special meeting of stockholders held on November 13, 2026.
Pursuant
to the Merger Agreement, at the Effective Time, by virtue of the Merger and without any action on the part of any party or the holders
of any securities of the Company or PubCo, (i) each share of common stock, par value $0.001 per share, of the Company (the “Company
Common Stock”), after giving effect to a reverse stock split of the Company Common Stock effected prior to the Effective Time
at a ratio of 1-for 12.62- (the “NYSE Reverse Split”), issued and outstanding immediately prior to the Effective
Time was converted into the right to receive one ordinary share of PubCo (each, a “PubCo Ordinary Share”), such that
the holders of Company Common Stock received, in the aggregate, 8,640,000 PubCo Ordinary Shares, representing approximately 4.80% of
the total issued and outstanding PubCo Ordinary Shares at the Closing (the “Merger Consideration”), and (ii) each
share of common stock of Merger Sub issued and outstanding immediately prior to the Effective Time was converted into one validly issued,
fully paid and non-assessable share of common stock of the Surviving Corporation. The shares of Company Common Stock entitled to receive
the Merger Consideration included shares issued upon the exercise or settlement of In the Money Impact Options and In the Money Impact
Warrants (each as defined in the Merger Agreement), if any.
At
the Effective Time, (i) each outstanding option to purchase Company Common Stock (each, an “Impact Option”) and each
outstanding warrant to purchase Company Common Stock (each, an “Impact Warrant”) that was not then vested or exercisable
became vested and exercisable in full immediately prior to the Effective Time, (ii) each In the Money Impact Option and In the Money
Impact Warrant was cancelled, and its holder became entitled to receive, immediately prior to the Effective Time, a number of shares
of Company Common Stock equal to the number of shares underlying such Impact Option or Impact Warrant, less shares withheld to satisfy
applicable tax withholding obligations, which shares were converted into the right to receive the Merger Consideration, and (iii) each
Impact Option and Impact Warrant with an exercise price equal to or greater than the Impact Closing Price (as defined in the Merger Agreement)
was cancelled for no consideration.
In
connection with the Share Exchange, PubCo issued at the Closing (i) 167,976,000 PubCo Ordinary Shares to the Zoar Shareholder, representing
approximately 94.02% of the total issued and outstanding PubCo Ordinary Shares at the Closing, (ii) 22,000 PubCo Ordinary Shares
to Frank D. Heuszel, the Company’s Chief Executive Officer (the “Compensation Shares”), (iii) 228,000 PubCo
Ordinary Shares to DSS, Inc. (the “DSS Shares”), and (iv) 1,800,000 PubCo Ordinary Shares to BMI Capital International
LLC, representing approximately 1.00% of the total issued and outstanding PubCo Ordinary Shares at the Closing.
The
PubCo Ordinary Shares issued in the Business Combination were registered under the Securities Act of 1933, as amended (the “Securities
Act”), under PubCo’s Registration Statement on Form F-4 (File No. 333-298856), which was declared effective by the U.S.
Securities and Exchange Commission (the “SEC”) on October 23, 2026. The PubCo Ordinary Shares are expected to begin
trading on the NYSE American LLC (“NYSE American”) under the symbol “ZOAR” on November 18, 2026.
The
foregoing description of the Merger, the Business Combination and the Merger Agreement does not purport to be complete and is qualified
in its entirety by reference to the full text of the Merger Agreement, copies of which are filed as Exhibits 2.1, 2.2 and 2.3 to this
Current Report on Form 8-K and are incorporated by reference into this Item 2.01.
The
information set forth in the Introductory Note of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.
Item
3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On
the Closing Date, the Company notified NYSE American that the Merger had been completed and requested that NYSE American (i) suspend
trading of the Company Common Stock prior to the open of trading on November 18, 2026, (ii) withdraw the Company’s Common Stock from
listing on NYSE American, and (iii) file with the SEC a notification of removal from listing on Form 25 to delist the Company Common
Stock from NYSE American and deregister the Company Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”). As a result, the Company Common Stock, which previously traded under the symbol “IBO,”
will no longer be listed on NYSE American. The delisting will be effective ten (10) days after the Form 25 is filed.
Additionally,
after the Form 25 becomes effective, the Company intends to file with the SEC a certification on Form 15 under the Exchange Act
requesting the deregistration of the Company Common Stock under Section 12(g) of the Exchange Act and the suspension of the Company’s
reporting obligations under Sections 13 and 15(d) of the Exchange Act.
The
information set forth in the Introductory Note and under Item 2.01 of this Current Report on Form 8-K is incorporated by reference into
this Item 3.01.
Item
3.03. Material Modification to Rights of Security Holders.
At
the Effective Time, each issued and outstanding share of Company Common Stock (after giving effect to the NYSE Reverse Split) was cancelled
and converted into the right to receive the Merger Consideration, and each Impact Option and Impact Warrant was treated as described
in Item 2.01. Accordingly, at the Effective Time, holders of Company Common Stock ceased to have any rights as stockholders of the Company,
other than the right to receive the Merger Consideration. Holders of PubCo Ordinary Shares hold the rights provided under PubCo’s
amended and restated memorandum and articles of association, which became effective simultaneously with or immediately following the
Share Exchange, and under the laws of the Cayman Islands.
The
information set forth in the Introductory Note and under Items 2.01, 3.01, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated
by reference into this Item 3.03.
Item
5.01. Changes in Control of Registrant.
At
the Effective Time, Merger Sub merged with and into the Company pursuant to the Merger Agreement. The Company continued as the surviving
corporation and became a wholly-owned subsidiary of PubCo. As a result, a change in control of the Company occurred. PubCo funded the
Merger Consideration through the issuance of PubCo Ordinary Shares and paid no cash consideration. Immediately following the Business
Combination, the Zoar Shareholder, Kanans Visvanats, holds approximately 94.02% of the issued and outstanding PubCo Ordinary Shares
and therefore controls a majority of the voting power of PubCo, and indirectly of the Company.
The
information set forth in the Introductory Note and under Items 2.01, 3.01, 3.03 and 5.02 of this Current Report on Form 8-K is incorporated
by reference into this Item 5.01.
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
Pursuant
to Section 2.5 of the Merger Agreement, at the Effective Time, each member of the Company’s board of directors, the Chief Financial
Officer, and the Chief Operating Officer resigned and ceased to hold office.
Also
pursuant to Section 2.5 of the Merger Agreement, at the Effective Time, the following were appointed as directors of the Board of Directors
of PubCo, the Company’s parent: Kanans Visvanats (Chairman), Donald Kalkofen, Michael Zajas, Evan Lim, Neha Kumari, Maduabuchi
Nelson Okey, Bang-Ning (Simon) Liu and David A. Sanders. The executive officers of PubCo are Kanans Visvanats (Chief Executive Officer
and Interim Chief Financial Officer), Adrian Anthony Simon Markland (Chief Operating Officer) and Sameer Ramesh Talim (Head of Sales
and Marketing). Each will hold office in accordance until his or her resignation or removal or until a successor is duly elected or appointed
and qualified.
Pursuant
to Section 3.2(d) of the Merger Agreement, as amended, PubCo issued the 22,000 Compensation Shares to Mr. Heuszel at the Closing. The
Compensation Shares were registered under the Registration Statement on Form F-4.
Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Pursuant
to Section 2.4 of the Merger Agreement, at the Effective Time, the articles of incorporation and bylaws of the Company, as in effect
immediately prior to the Effective Time, were amended and restated in their entirety to read in the form of the articles of incorporation
and bylaws of Merger Sub as in effect immediately prior to the Effective Time, except that (i) the name of the Surviving Corporation
was changed to “Dr Ashleys USA Inc.”, (ii) the NYSE Reverse Split was effected, and (iii) PubCo made such other changes
as it deemed appropriate. The Company previously announced and disclosed the NYSE Reverse Split on a Current Report on Form 8-K filed
with the SEC on October 9, 2026, and is incorporated herein by reference.
The
information set forth in Item 2.01 is incorporated by reference into this Item 5.03.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit
No. |
|
Description
of Exhibit |
| 2.1 |
|
Merger and Share Exchange Agreement, dated as of June 21, 2025, by and among Dr Ashleys Limited, Impact BioMedical Inc., Dr Ashleys Nevada Sub, Inc., Dr Ashleys Bio Labs Limited and Kanans Visvanats (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed on June 23, 2025). |
| 2.2 |
|
Amended and Restated Amendment to the Merger and Share Exchange Agreement, dated as of June 30, 2026. |
| 2.3 |
|
Second Amended and Restated Amendment to the Merger and Share Exchange Agreement, dated as of August 13, 2026. |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K
to be signed on its behalf by the undersigned hereunto duly authorized.
| |
IMPACT
BIOMEDICAL INC. |
| |
|
|
| Date:
November 18, 2026 |
By: |
/s/
Frank D. Heuszel |
| |
Name: |
Frank
D. Heuszel |
| |
Title: |
Chief
Executive Officer |